Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Testosterone bounce, a rise in testosterone levels after initial suppression, is a promising biomarker for predicting overall survival and cancer-specific survival in prostate cancer patients treated with degarelix acetate.
Area Of Science
- Oncology
- Endocrinology
Background
- Investigating the clinical significance of testosterone (T) level fluctuations during degarelix acetate therapy for prostate cancer.
- Establishing a cut-off level of 20 ng/dL for T to predict treatment outcomes.
Purpose Of The Study
- To evaluate the predictive value of testosterone dynamics, including T bounce, for survival outcomes in prostate cancer patients.
- To clarify the role of T levels as prognostic factors in patients receiving degarelix acetate.
Main Methods
- Retrospective analysis of 120 prostate cancer patients treated with degarelix acetate.
- Evaluation of nadir T levels, max T levels, and T bounce (nadir T < 20 ng/dL and max T ≥ 20 ng/dL) as predictors.
- Assessment of overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS).
Main Results
- T bounce occurred in 50% of patients (60/120).
- T bounce was significantly associated with favorable OS (p=0.0019) and CSS (p=0.0013), but not PFS (p=0.92).
- In a subgroup analysis, T bounce predicted favorable OS and CSS after biochemical recurrence.
Conclusions
- Testosterone bounce, defined by specific T level thresholds, is a promising biomarker for predicting OS and CSS.
- This finding is particularly relevant for prostate cancer patients undergoing treatment with degarelix acetate.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...